Impact of baseline medications on real-world overall survival in immune checkpoint inhibitor-treated patients with cancer in the RADIOHEAD cohort | Synapse
April 21, 2026Open Access
Impact of baseline medications on real-world overall survival in immune checkpoint inhibitor-treated patients with cancer in the RADIOHEAD cohort
Key Points
The central aim is to evaluate how baseline medications affect overall survival in patients treated with immune checkpoint inhibitors for cancer.
Analysis of patients from the RADIOHEAD cohort treated with immune checkpoint inhibitors.
Assessment of various baseline medications and their correlation with overall survival.
Identified significant associations between certain baseline medications and improved overall survival rates.
Highlighted variability in survival outcomes depending on medication use.
Abstract
This study was supported in part by the National Institutes of Health and the Parker Institute for Cancer Immunotherapy (PICI).